Phase I/II study of complementary therapy using curcumin for gemcitabine-refractory pancreatic cancer patients
Phase 1
- Conditions
- Advanced pancreatic cancer patients who get refractory to gemcitabine-based chemotherapy
- Registration Number
- JPRN-UMIN000001386
- Lead Sponsor
- Kyoto University Hospital, Outpatient Oncology Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with interstitial pneumonia or pulmonary fibrosis. 2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months 3. Patients with severe infection. 4. Patients with history of severe drug allegy 5. Patients with other serious comorbid diseases 6. Patients with advanced cancer other than pancreatic cancer 7. Pregnant women or patients who wish pregnant 8. Patients with mental diseases 9. Patients who are judged inappropriate for the entry into the study by the investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I; Safety Phase II; Feasibility of complementary therapy using curcumin
- Secondary Outcome Measures
Name Time Method